{"id":132107,"date":"2026-09-17T12:41:17","date_gmt":"2026-09-17T12:41:17","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/132107\/"},"modified":"2026-09-17T12:41:17","modified_gmt":"2026-09-17T12:41:17","slug":"roche-taps-dualitas-in-1b-bispecific-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/132107\/","title":{"rendered":"Roche taps Dualitas in $1B bispecific deal"},"content":{"rendered":"<p>Why it matters: Bispecific antibodies, long concentrated in oncology, are increasingly moving into autoimmune and inflammatory diseases. Roche is already developing several approaches in the field, and the Dualitas deal gives it a way to search much more broadly for new target combinations.<\/p>\n<p>By the numbers: Roche will pay Dualitas $36.5 million (\u20ac31.8 million) upfront. Research, development and commercial milestones could bring the total deal value to $1 billion (\u20ac871 million), plus tiered royalties.<\/p>\n<p>Dualitas plans to functionally screen more than 300,000 bispecific combinations under the collaboration, in \u201cwhat is believed to be one of the largest-scale bispecific discovery endeavors,\u201d according to the company\u2019s <a href=\"https:\/\/www.dualitastx.com\/news\/091726\/\" rel=\"nofollow noopener\" target=\"_blank\">announcement<\/a>.<br \/>\nOnce candidates are identified, Roche will take responsibility for preclinical development, regulatory activities, manufacturing and commercialization.<\/p>\n<p>How it works: Dualitas\u2019 DualScreen platform searches for pairs of cell-surface targets that work better together than either target does alone. The company\u2019s own bispecifics combine an antibody against a therapeutic target with a \u201cproximity engager\u201d designed to bring cell-surface proteins together and amplify the biological effect. Rather than starting with a predetermined pair of targets, DualScreen can test large numbers of combinations in functional assays.<\/p>\n<p>Backstory: Dualitas was founded in 2023 and emerged from stealth in September 2025 with a $65 million Series A, co-led by Versant Ventures and Qiming Venture Partners USA. Eli Lilly and Roche subsidiary Chugai\u2019s venture fund were among the strategic investors.<\/p>\n<p>Its internal pipeline includes DTX-102 for rheumatoid arthritis, DTX-103 for allergic disease and DTX-101 for dermatologic and gastrointestinal autoimmune diseases. DTX-102 is currently in IND-enabling studies, with Dualitas saying its pipeline is expected to begin entering the clinic next year.<\/p>\n<p>The big picture: Roche has been rapidly adding new antibody approaches in immunology. Earlier this month, it licensed <a href=\"https:\/\/european-biotechnology.com\/latest-news\/roche-reloads-b-cell-strategy-with-1-53b-simcere-deal\/\" rel=\"nofollow noopener\" target=\"_blank\">Simcere Zaiming\u2019s CD79a\u00d7CD19\u00d7CD3 trispecific<\/a> SIM0660 for up to $1.53 billion. The Dualitas collaboration now broadens that search beyond individual assets to large-scale discovery of new bispecific combinations.<\/p>\n<p>Yes, but: Not every attempt has worked: Roche discontinued the CD19\u00d7CD3 bispecific RG6382 in lupus this summer after concluding that the molecule did not have the characteristics needed to continue development in the indication.<\/p>\n","protected":false},"excerpt":{"rendered":"Why it matters: Bispecific antibodies, long concentrated in oncology, are increasingly moving into autoimmune and inflammatory diseases. Roche&hellip;\n","protected":false},"author":2,"featured_media":132108,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[14272,134],"class_list":["post-132107","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-licensing","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117286435916062976","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/132107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=132107"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/132107\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/132108"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=132107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=132107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=132107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}